All Stories

  1. Dual transcriptomics suggests trophoblastic sequestration and splicing blockade induced by Trypanosoma cruzi during in vitro infection
  2. The reticulocyte restriction: invasion ligand RBP1a of Plasmodium vivax targets human TfR1, prohibitin-2, and basigin
  3. Characterisation of the erythrocyte invasion phenotype of FCB-2: A South American P. falciparum reference strain
  4. Immunopeptidomics of Salmonella enterica Serovar Typhimurium-Infected Pig Macrophages Genotyped for Class II Molecules
  5. Metagenome-assembled genomes (MAGs) suggest an acetate-driven protective role in gut microbiota disrupted by Clostridioides difficile
  6. A review concerning the breast cancer-related tumour microenvironment
  7. Identifying major histocompatibility complex class II-DR molecules in bovine and swine peripheral blood monocyte-derived macrophages using mAb-L243
  8. Babesia bovis RON2 binds to bovine erythrocytes through a highly conserved epitope
  9. Self-assembling peptides: Perspectives regarding biotechnological applications and vaccine development
  10. Strategies for studying immune and non-immune human and canine mammary gland cancer tumour infiltrate
  11. Therapeutic Use of the Antimicrobial Peptide PNR20 to Resolve Disseminated Candidiasis in a Murine Model
  12. Acquisition site-based remodelling of Clostridium perfringens- and Clostridioides difficile-related gut microbiota
  13. Invasion-inhibitory peptides chosen by natural selection analysis as an antimalarial strategy
  14. Differential NRAMP1gene’s D543N genotype frequency: Increased risk of contracting tuberculosis among Venezuelan populations
  15. In Vitro Antifungal Activity of Three Synthetic Peptides against Candida auris and Other Candida Species of Medical Importance
  16. Transmission of Furcraea necrotic streak virus (FNSV) by Olpidium virulentus
  17. Clinical manifestations and immune response to tuberculosis
  18. Plasmodium falciparum rhoptry neck protein 4 has conserved regions mediating interactions with receptors on human erythrocytes and hepatocyte membrane
  19. Adjuvants approved for human use: What do we know and what do we need to know for designing good adjuvants?
  20. Developing Anti-Babesia bovis Blood Stage Vaccines: A New Perspective Regarding Synthetic Vaccines
  21. Peptide-pulsed dendritic cells’ immunomodulating effect regarding Mycobacterium tuberculosis growth in macrophages
  22. Identification of Babesia bovis MSA-1 functionally constraint regions capable of binding to bovine erythrocytes
  23. Changes in the Cervical Microbiota of Women with Different High-Risk Human Papillomavirus Loads
  24. The Black Box of Cellular and Molecular Events of Plasmodium vivax Merozoite Invasion into Reticulocytes
  25. Microbial Interdomain Interactions Delineate the Disruptive Intestinal Homeostasis in Clostridioides difficile Infection
  26. Stereo electronic principles for selecting fully-protective, chemically-synthesised malaria vaccines
  27. Establishing and characterising a new cell line from Calliphora vicina (diptera: calliphoridae) fly embryonic tissues
  28. SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population
  29. Diagnostic Potential of the Serological Response to Synthetic Peptides from Mycobacterium tuberculosis Antigens for Discrimination Between Active and Latent Tuberculosis Infections
  30. The Cellular and Molecular Interaction Between Erythrocytes and Plasmodium falciparum Merozoites
  31. The prevalence of Chlamydia psittaci in confiscated Psittacidae in Colombia
  32. Comparing Class II MHC DRB3 Diversity in Colombian Simmental and Simbrah Cattle Across Worldwide Bovine Populations
  33. Cervical cancer screening programme attendance and compliance predictors regarding Colombia’s Amazon region
  34. How to Combat Gram-Negative Bacteria Using Antimicrobial Peptides: A Challenge or an Unattainable Goal?
  35. Structural Modelling of KCNQ1 and KCNH2 Double Mutant Proteins, Identified in Two Severe Long QT Syndrome Cases, Reveals New Insights into Cardiac Channelopathies
  36. Trichomonas vaginalis follow-up and persistence in Colombian women
  37. Molecular characterisation of parvorder Platyrrhini IgG sub-classes
  38. Mycobacterium tuberculosis Rv0292 Protein Peptides Could be Included in a Synthetic Anti-tuberculosis Vaccine
  39. Risk factor for breast cancer development under exposure to bovine leukemia virus in Colombian women: A case-control study
  40. Nanovaccines against Animal Pathogens: The Latest Findings
  41. The First Chemically-Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use
  42. Genetic diversity and population structure of Rhipicephalus sanguineus sensu lato across different regions of Colombia
  43. ESAT-6 and Ag85A Synthetic Peptides as Candidates for an Immunodiagnostic Test in Children with a Clinical Suspicion of Tuberculosis
  44. Identifying HLA DRB1-DQB1 alleles associated with Chlamydia trachomatis infection and in silico prediction of potentially-related peptides
  45. Mechanisms Associated with Trypanosoma cruzi Host Target Cell Adhesion, Recognition and Internalization
  46. Gut microbiota composition in health-care facility-and community-onset diarrheic patients with Clostridioides difficile infection
  47. MHCBI: a pipeline for calculating peptide-MHC binding energy using semi-empirical quantum mechanical methods with explicit/implicit solvent models
  48. Co-Circulation of Bovine Leukemia Virus Haplotypes among Humans, Animals, and Food Products: New Insights of Its Zoonotic Potential
  49. Gut microbiota profiles in diarrheic patients with co-occurrence of Clostridioides difficile and Blastocystis
  50. A comparative analysis of SLA-DRB1 genetic diversity in Colombian (creoles and commercial line) and worldwide swine populations
  51. Two 20-Residue-Long Peptides Derived from Plasmodium vivax Merozoite Surface Protein 10 EGF-Like Domains Are Involved in Binding to Human Reticulocytes
  52. T Cell Peptides Derived from Invasive Stages of Schistosoma mansoni as Potential Schistosomiasis Vaccine
  53. Babesia Bovis Ligand-Receptor Interaction: AMA-1 Contains Small Regions Governing Bovine Erythrocyte Binding
  54. A novel platform for peptide-mediated affinity capture and LC-MS/MS identification of host receptors involved in Plasmodium invasion
  55. Characterising four Sarconesiopsis magellanica (Diptera: Calliphoridae) larval fat body-derived antimicrobial peptides
  56. The molecular basis for peptide-based antimalarial vaccine development targeting erythrocyte invasion by P. falciparum
  57. Updating changes in human gut microbial communities associated with Clostridioides difficile infection
  58. A Comprehensive Review of the Immunological Response against Foot-and-Mouth Disease Virus Infection and Its Evasion Mechanisms
  59. Robust, Comprehensive Molecular, and Phenotypical Characterisation of Atypical Candida albicans Clinical Isolates From Bogotá, Colombia
  60. Loop-Mediated Isothermal Amplification as Point-of-Care Diagnosis for Neglected Parasitic Infections
  61. Antibodies targeting Mycobacterium tuberculosis peptides inhibit mycobacterial entry to infection target cells
  62. Una hoja de ruta para la Vacuna COVID 19 en Colombia, un reto posible
  63. Molecular Markers for Detecting Schistosoma Species by Loop-Mediated Isothermal Amplification
  64. Hotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion
  65. Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases
  66. Shorter Antibacterial Peptide Having High Selectivity for E. coli Membranes and Low Potential for Inducing Resistance
  67. Strong-LAMP Assay Based on a Strongyloides spp.-Derived Partial Sequence in the 18S rRNA as Potential Biomarker for Strongyloidiasis Diagnosis in Human Urine Samples
  68. Enhanced virulence of Beauveria bassiana against Diatraea saccharalis using a soluble recombinant enzyme with endo- and exochitinase activity
  69. Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
  70. Identifying the HLA DRB1-DQB1 molecules and predicting epitopes associated with high-risk HPV infection clearance and redetection
  71. Occurrence of Blastocystis in Patients with Clostridioides difficile Infection
  72. Inferring Plasmodium vivax protein biology by using omics data
  73. Plasmodium vivax Cell Traversal Protein for Ookinetes and Sporozoites (CelTOS) Functionally Restricted Regions Are Involved in Specific Host-Pathogen Interactions
  74. A Trypanosoma cruzi Genome Tandem Repetitive Satellite DNA Sequence as a Molecular Marker for a LAMP Assay for Diagnosing Chagas’ Disease
  75. Plasmodium falciparum pre-erythrocytic stage vaccine development
  76. Sexual forms obtained in a continuous in vitro cultured Colombian strain of Plasmodium falciparum (FCB2)
  77. From a basic to a functional approach for developing a blood stage vaccine against Plasmodium vivax
  78. Major Histocompatibility Complex Class II (DRB3) Genetic Diversity in Spanish Morucha and Colombian Normande Cattle Compared to Taurine and Zebu Populations
  79. NHP-immunome: A translational research-oriented database of non-human primate immune system proteins
  80. Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model
  81. Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines
  82. Assessing Peptide Binding to MHC II: An Accurate Semiempirical Quantum Mechanics Based Proposal
  83. Peptides Derived of Kunitz-Type Serine Protease Inhibitor as Potential Vaccine Against Experimental Schistosomiasis
  84. Using next‐generation sequencing for characterising HLA‐ DRB1 and DQB1 loci in a cohort of Colombian women
  85. Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia
  86. Complement Receptor 1 availability on red blood cell surface modulates Plasmodium vivax invasion of human reticulocytes
  87. High frequency of toxigenic Clostridium difficile and Clostridium perfringens coinfection among diarrheic patients at health care facility-onset (HCFO) and community-onset (CO) centers in Bogotá, Colombia
  88. Sarconesin II, a New Antimicrobial Peptide Isolated from Sarconesiopsis magellanica Excretions and Secretions
  89. Specific Binding Peptides from Rv3632: A Strategy for Blocking Mycobacterium tuberculosis Entry to Target Cells?
  90. An epidemiological and molecular study regarding the spread of vancomycin-resistant Enterococcus faecium in a teaching hospital in Bogotá, Colombia 2016
  91. Behavior and abundance of Anopheles darlingi in communities living in the Colombian Amazon riverside
  92. Immunocompetent patient with a brain abscess caused by Nocardia beijingensis in Latin America
  93. Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field
  94. Parasite-Related Genetic and Epigenetic Aspects and Host Factors Influencing Plasmodium falciparum Invasion of Erythrocytes
  95. Comparative genomics identifies potential virulence factors in Clostridium tertium and C. paraputrificum
  96. Cryptosporidium spp. CP15 and CSL protein-derived synthetic peptides’ immunogenicity and in vitro seroneutralisation capability
  97. Sarconesin: Sarconesiopsis magellanica Blowfly Larval Excretions and Secretions With Antibacterial Properties
  98. Plasmodium vivax Pv12 B-cell epitopes and HLA-DRβ1*-dependent T-cell epitopes in vitro antigenicity
  99. Association of HIV status with infection by multiple HPV types
  100. On the Evolution and Function of Plasmodium vivax Reticulocyte Binding Surface Antigen (pvrbsa)
  101. Correction to: Comparison of healing of full-thickness skin wounds grafted with multidirectional or unidirectional autologous artificial dermis: differential delivery of healing biomarkers
  102. Unveiling the Multilocus Sequence Typing (MLST) Schemes and Core Genome Phylogenies for Genotyping Chlamydia trachomatis
  103. Plasmodium vivax in vitro continuous culture: the spoke in the wheel
  104. Self-assembling functional programmable protein array for studying protein–protein interactions in malaria parasites
  105. Diagnostic accuracy of combinations of serological biomarkers for identifying clinical tuberculosis
  106. In silico and in vitro analysis of boAP3d1 protein interaction with bovine leukaemia virus gp51
  107. The in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile
  108. Towards designing a synthetic antituberculosis vaccine: The Rv3587c peptide inhibits mycobacterial entry to host cells
  109. Comparison of healing of full-thickness skin wounds grafted with multidirectional or unidirectional autologous artificial dermis: differential delivery of healing biomarkers
  110. Specific β-Turns Precede PPIIL Structures Binding to Allele-Specific HLA-DRβ1* PBRs in Fully-Protective Malaria Vaccine Components
  111. Micro-epidemiology of mixed-species malaria infections in a rural population living in the Colombian Amazon region
  112. Simultaneous detection of Plasmodium vivax dhfr, dhps, mdr1 and crt-o resistance-associated mutations in the Colombian Amazonian region
  113. Receptor-ligand and parasite protein-protein interactions in Plasmodium vivax : Analysing rhoptry neck proteins 2 and 4
  114. Quantifying intracellular Mycobacterium tuberculosis : An essential issue for in vitro assays
  115. Mycobacterium tuberculosis H37Rv LpqG Protein Peptides Can Inhibit Mycobacterial Entry through Specific Interactions
  116. Easy and fast method for expression and native extraction of Plasmodium vivax Duffy binding protein fragments
  117. Identifying Potential Plasmodium vivax Sporozoite Stage Vaccine Candidates: An Analysis of Genetic Diversity and Natural Selection
  118. Evaluating the anti-leishmania activity of Lucilia sericata and Sarconesiopsis magellanica blowfly larval excretions/secretions in an in vitro model
  119. A novel loop-mediated isothermal amplification-based test for detecting Neospora caninum DNA
  120. Community-acquired infection with hypervirulent Clostridium difficile isolates that carry different toxin and antibiotic resistance loci: a case report
  121. Purification of Trypanosoma cruzi metacyclic trypomastigotes by ion exchange chromatography in sepharose-DEAE, a novel methodology for host-pathogen interaction studies
  122. Novel genes and mutations in patients affected by recurrent pregnancy loss
  123. Bovine leukaemia virus DNA in fresh milk and raw beef for human consumption
  124. Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans
  125. Plasmodium vivax ligand-receptor interaction: PvAMA-1 domain I contains the minimal regions for specific interaction with CD71+ reticulocytes
  126. Critical role of HLA-DRβ* binding peptides' peripheral flanking residues in fully-protective malaria vaccine development
  127. PvGAMA reticulocyte binding activity: predicting conserved functional regions by natural selection analysis
  128. Characterising PvRBSA: an exclusive protein from Plasmodium species infecting reticulocytes
  129. New mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing
  130. Determining Clostridium difficile intra-taxa diversity by mining multilocus sequence typing databases
  131. Identifying and characterising PPE7 (Rv0354c) high activity binding peptides and their role in inhibiting cell invasion
  132. What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?
  133. Multiple high-risk HPV genotypes are grouped by type and are associated with viral load and risk factors
  134. pELMO, an optimised in-house cloning vector
  135. Transcriptome profiling of gene expression during immunisation trial against Fasciola hepatica: identification of genes and pathways involved in conferring immunoprotection in a murine model
  136. Multi-site protein-ligand quantum prediction
  137. The Aotus nancymaae erythrocyte proteome and its importance for biomedical research
  138. Far from the Madding Crowd: the Molecular Basis for Immunological Escape ofPlasmodium falciparum
  139. The effect of Lucilia sericata - and Sarconesiopsis magellanica -derived larval therapy on Leishmania panamensis
  140. Plasmodium malariae in the Colombian Amazon region: you don’t diagnose what you don’t suspect
  141. Evidence of functional divergence in MSP7 paralogous proteins: a molecular-evolutionary and phylogenetic analysis
  142. The Prevalence of High-Risk HPV Types and Factors Determining Infection in Female Colombian Adolescents
  143. Size polymorphism and low sequence diversity in the locus encoding the Plasmodium vivax rhoptry neck protein 4 (PvRON4) in Colombian isolates
  144. TCR-contacting residues orientation and HLA-DRβ* binding preference determine long-lasting protective immunity against malaria
  145. High Plasmodium malariae Prevalence in an Endemic Area of the Colombian Amazon Region
  146. Evaluating the Biological Cycle and Reproductive and Population Parameters ofCalliphora vicina(Diptera: Calliphoridae) Reared on Three Different Diets
  147. Mycobacterium tuberculosis PE9 protein has high activity binding peptides which inhibit target cell invasion
  148. Evaluating Sarconesiopsis magellanica blowfly-derived larval therapy and comparing it to Lucilia sericata-derived therapy in an animal model
  149. Chlamydia trachomatis Frequency in a Cohort of HPV-Infected Colombian Women
  150. Immune protection-inducing protein structures (IMPIPS) against malaria: the weapons needed for beating Odysseus
  151. Evidence of recent interspecies horizontal gene transfer regarding nucleopolyhedrovirus infection of Spodoptera frugiperda
  152. Characterising atypical Candida albicans clinical isolates from six third-level hospitals in Bogotá, Colombia
  153. Cell-Peptide Specific Interaction Can InhibitMycobacterium tuberculosis H37RvInfection
  154. Recent advances in the development of a chemically synthesised anti-malarial vaccine
  155. Inferring natural selection signals in Plasmodium vivax -encoded proteins having a potential role in merozoite invasion
  156. IMPIPS: The Immune Protection-Inducing Protein Structure Concept in the Search for Steric-Electron and Topochemical Principles for Complete Fully-Protective Chemically Synthesised Vaccine Development
  157. The DNA load of six high-risk human papillomavirus types and its association with cervical lesions
  158. New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study
  159. The effects of Sarconesiopsis magellanica larvae (Diptera: Calliphoridae) excretions and secretions on fibroblasts
  160. Terapia larval en la curación de heridas
  161. Combination of Mycobacterium tuberculosis immunodominant peptides and serum host response biomarkers for the diagnosis of tuberculosis
  162. Determining the Plasmodium vivax VCG-1 strain blood stage proteome
  163. Evaluating the Effect ofSarconesiopsis magellanica(Diptera: Calliphoridae) Larvae-Derived Haemolymph and Fat Body Extracts on Chronic Wounds in Diabetic Rabbits
  164. The Plasmodium vivax rhoptry neck protein 5 is expressed in the apical pole of Plasmodium vivax VCG-1 strain schizonts and binds to human reticulocytes
  165. Mce4F Mycobacterium tuberculosis protein peptides can inhibit invasion of human cell lines
  166. In Vitro and In Vivo Studies for Assessing the Immune Response and Protection-Inducing Ability Conferred by Fasciola hepatica-Derived Synthetic Peptides Containing B- and T-Cell Epitopes
  167. Sarconesiopsis magellanica (Diptera: Calliphoridae) excretions and secretions have potent antibacterial activity
  168. Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study
  169. Specific Interaction betweenMycobacterium tuberculosisLipoprotein-derived Peptides and Target Cells Inhibits Mycobacterial EntryIn Vitro
  170. Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia
  171. Characterising a Microsatellite for DRB Typing in Aotus vociferans and Aotus nancymaae (Platyrrhini)
  172. Th1 and Th2 immune response to P30 and ROP18 peptides in human toxoplasmosis
  173. Gauche+ side-chain orientation as a key factor in the search for an immunogenic peptide mixture leading to a complete fully protective vaccine
  174. Plasmodium falciparum rhoptry neck protein 5 peptides bind to human red blood cells and inhibit parasite invasion
  175. Using the PfEMP1 Head Structure Binding Motif to Deal a Blow at Severe Malaria
  176. Heterogeneous genetic diversity pattern in Plasmodium vivax genes encoding merozoite surface proteins (MSP) -7E, −7F and -7L
  177. Low genetic diversity and functional constraint in loci encoding Plasmodium vivax P12 and P38 proteins in the Colombian population
  178. Low genetic diversity in the locus encoding the Plasmodium vivax P41 protein in Colombia’s parasite population
  179. Proteolytic activity regarding Sarconesiopsis magellanica (Diptera: Calliphoridae) larval excretions and secretions
  180. Sarconesiopsis magellanica (Diptera: Calliphoridae) life-cycle, reproductive and population parameters using different diets under laboratory conditions
  181. Identification and Diversity of Killer Cell Ig-Like Receptors in Aotus vociferans, a New World Monkey
  182. Rv1268c protein peptide inhibiting Mycobacterium tuberculosis H37Rv entry to target cells
  183. Classical Molecular Tests Using Urine Samples as a Potential Screening Tool for Human Papillomavirus Detection in Human Immunodeficiency Virus-Infected Women
  184. Reticulocytes:Plasmodium vivaxtarget cells
  185. Rh1 high activity binding peptides inhibit high percentages of Plasmodium falciparum FVO strain invasion
  186. Immunologic evaluation and validation of methods using synthetic peptides derived from Mycobacterium tuberculosis for the diagnosis of tuberculosis infection
  187. Enterococcus faecalis internalization in human umbilical vein endothelial cells (HUVEC)
  188. Mammaglobin peptide as a novel biomarker for breast cancer detection
  189. Functional, biochemical and 3D studies ofMycobacterium tuberculosisprotein peptides for an effective anti-tuberculosis vaccine
  190. Human Papillomavirus Detection from Human Immunodeficiency Virus-Infected Colombian Women's Paired Urine and Cervical Samples
  191. Annotation and characterization of the Plasmodium vivax rhoptry neck protein 4 (PvRON4)
  192. Characterizing PvARP, a novel Plasmodium vivax antigen
  193. The GPI-anchored 6-Cys Protein Pv12 is Present in Detergent-resistant Microdomains of Plasmodium vivax Blood Stage Schizonts
  194. Mycobacterium tuberculosis surface protein Rv0227c contains high activity binding peptides which inhibit cell invasion
  195. Vaccines againstPlasmodium vivax: a research challenge
  196. The diagnostic performance of classical molecular tests used for detecting human papillomavirus
  197. Genetic Diversity and Selection in Three Plasmodium vivax Merozoite Surface Protein 7 (Pvmsp-7) Genes in a Colombian Population
  198. The role of Mycobacterium tuberculosis Rv3166c protein-derived high-activity binding peptides in inhibiting invasion of human cell lines
  199. A single amino acid change in the Plasmodium falciparum RH5 (PfRH5) human RBC binding sequence modifies its structure and determines species-specific binding activity
  200. 3D structure and immunogenicity of Plasmodium falciparum sporozoite induced associated protein peptides as components of fully-protective anti-malarial vaccine
  201. Detection by PCR of human papillomavirus in Colombia: Comparison of GP5+/6+ and MY09/11 primer sets
  202. Bacterial Translocation in Abdominal Trauma and Postoperative Infections
  203. Identification of Plasmodium vivax Proteins with Potential Role in Invasion Using Sequence Redundancy Reduction and Profile Hidden Markov Models
  204. Binding activity, structure, and immunogenicity of synthetic peptides derived from Plasmodium falciparum CelTOS and TRSP proteins
  205. Synthetic peptides from two Pf sporozoite invasion-associated proteins specifically interact with HeLa and HepG2 cells
  206. Identifying and characterizing a member of the RhopH1/Clag family in Plasmodium vivax
  207. Peptides derived from Mycobacterium tuberculosis Rv2301 protein are involved in invasion to human epithelial cells and macrophages
  208. Structural and Immunological Principles Leading to Chemically Synthesized, Multiantigenic, Multistage, Minimal Subunit-Based Vaccine Development
  209. Frequency of Human Papillomavirus Infection, Coinfection, and Association with Different Risk Factors in Colombia
  210. Identification of the Plasmodium falciparum rhoptry neck protein 5 (PfRON5)
  211. Low genetic polymorphism of merozoite surface proteins 7 and 10 in Colombian Plasmodium vivax isolates
  212. Distribution Patterns of Infection with Multiple Types of Human Papillomaviruses and Their Association with Risk Factors
  213. The Mycobacterium tuberculosis membrane protein Rv0180c: Evaluation of peptide sequences implicated in mycobacterial invasion of two human cell lines
  214. Plasmodium vivax lineages: geographical distribution, tandem repeat polymorphism, and phylogenetic relationship
  215. Characterisation and comparative analysis of MHC-DPA1 exon 2 in the owl monkey (Aotus nancymaae)
  216. Identification, characterization and antigenicity of the Plasmodium vivax rhoptry neck protein 1 (PvRON1)
  217. Molecular modeling and in silico characterization of Mycobacterium tuberculosis TlyA: Possible misannotation of this tubercle bacilli-hemolysin
  218. NClassG+: A classifier for non-classically secreted Gram-positive bacterial proteins
  219. PvRON2, a new Plasmodium vivax rhoptry neck antigen
  220. Conserved regions of the Plasmodium falciparum rhoptry-associated protein 3 mediate specific host-pathogen interactions during invasion of red blood cells
  221. Evaluation of the antigenicity of universal epitopes from PvDBPII in individuals exposed to Plasmodium vivax malaria
  222. Conserved high activity binding peptides from the Plasmodium falciparum Pf34 rhoptry protein inhibit merozoites in vitro invasion of red blood cells
  223. Mechanisms of genetically-based resistance to malaria
  224. Computational Prediction and Experimental Assessment of Secreted/Surface Proteins from Mycobacterium tuberculosis H37Rv
  225. Conserved High Activity Binding Peptides are Involved in Adhesion of Two Detergent-Resistant Membrane-Associated Merozoite Proteins to Red Blood Cells during Invasion
  226. Differential expansion of the merozoite surface protein (msp)-7 gene family in Plasmodium species under a birth-and-death model of evolution
  227. Conserved regions from Plasmodium falciparum MSP11 specifically interact with host cells and have a potential role during merozoite invasion of red blood cells
  228. HLA class II polymorphism in Latin American patients with multiple sclerosis
  229. 3D Analysis of the TCR/pMHCII Complex Formation in Monkeys Vaccinated with the First Peptide Inducing Sterilizing Immunity against Human Malaria
  230. Sequences of the Plasmodium falciparum cytoadherence-linked asexual protein 9 implicated in malaria parasite invasion to erythrocytes
  231. Limited genetic polymorphism of the Plasmodium vivax low molecular weight rhoptry protein complex in the Colombian population
  232. Well-Defined Regions of thePlasmodium falciparumReticulocyte Binding Protein Homologue 4 Mediate Interaction with Red Blood Cell Membrane
  233. Peptides from the Mycobacterium tuberculosis Rv1980c protein involved in human cell infection: insights into new synthetic subunit vaccine candidates
  234. Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: Potential TB vaccine candidate antigen
  235. Atomic fidelity of subunit-based chemically-synthesized antimalarial vaccine components
  236. Identification and characterization of the Plasmodium vivax thrombospondin-related apical merozoite protein
  237. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection
  238. Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34)
  239. Synthetic peptides from conserved regions of the Plasmodium falciparum early transcribed membrane and ring exported proteins bind specifically to red blood cell proteins
  240. Toxoplasma gondii: P30 peptides recognition pattern in human toxoplasmosis
  241. Fine mapping of Plasmodium falciparum ribosomal phosphoprotein PfP0 revealed sequences with highly specific binding activity to human red blood cells
  242. Immunogenicity and protection-inducing ability of recombinant Plasmodium vivax rhoptry-associated protein 2 in Aotus monkeys: A potential vaccine candidate
  243. Prevalence of HPV-DNA and Anti-HPV Antibodies in Women From Girardot, Colombia
  244. Validating subcellular localization prediction tools with mycobacterial proteins
  245. Prevalence of infection with high-risk human papillomavirus in women in Colombia
  246. Identification and evaluation of universal epitopes in Plasmodium vivax Duffy binding protein
  247. The Plasmodium vivax Pv41 surface protein: Identification and characterization
  248. Characterisation of the Plasmodium vivax Pv38 antigen
  249. Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines
  250. Specificity of L1 Peptides versus Virus-Like Particles for Detection of Human Papillomavirus-Positive Cervical Lesions in Females Attending Engativa Hospital, Bogota, Colombia
  251. Characterization ofPlasmodium falciparumintegral membrane protein Pf25-IMP and identification of its red blood cell binding sequences inhibiting merozoite invasion in vitro
  252. Peptides derived from the Mycobacterium tuberculosis Rv1490 surface protein implicated in inhibition of epithelial cell entry: Potential vaccine candidates?
  253. Functional characterization of Mycobacterium tuberculosis Rv2969c membrane protein
  254. Shifting the Polarity of some Critical Residues in Malarial Peptides Binding to Host Cells is a Key Factor in Breaking Conserved Antigens Code of Silence
  255. Emerging Rules for Subunit-Based, Multiantigenic, Multistage Chemically Synthesized Vaccines
  256. Characterizing theMycobacterium tuberculosisRv2707 protein and determining its sequences which specifically bind to two human cell lines
  257. Quantitative flow cytometric monitoring of invasion of epithelial cells by Mycobacterium tuberculosis
  258. The Mycobacterium tuberculosis membrane protein Rv2560 − biochemical and functional studies
  259. A Novel Methodology for Characterizing and Predicting Protein Functional Sites
  260. Characterizing and Predicting Catalytic Residues in Enzyme Active Sites Based on Local Properties: A Machine Learning Approach
  261. Synthetic genes: a tool for identifying human papillomavirus genotypes by hybridization and polymerase chain reaction-based assays
  262. A pre-PEXEL histidine-rich protein II erythrocyte binding peptide as a new way for anti-malarial vaccine development
  263. Identifying and characterising the Plasmodium falciparum RhopH3 Plasmodium vivax homologue
  264. The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys
  265. Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization
  266. Functional, structural, and immunological compartmentalisation of malaria invasive proteins
  267. Characterisation of Plasmodium falciparum RESA-like protein peptides that bind specifically to erythrocytes and inhibit invasion
  268. Cloning, expression, and characterisation of a Plasmodium vivax MSP7 family merozoite surface protein
  269. High polymorphism in Plasmodium vivax merozoite surface protein-5 (MSP5)
  270. The Plasmodium vivax rhoptry-associated protein 1
  271. Plasmodium falciparum TryThrA antigen synthetic peptides block in vitro merozoite invasion to erythrocytes
  272. Identification of five different IGHV gene families in owl monkeys (Aotus nancymaae)
  273. Identifying putativeMycobacterium tuberculosisRv2004c protein sequences that bind specifically to U937 macrophages and A549 epithelial cells
  274. A B-lymphocyte binding peptide from BNRF1 induced antibodies inhibiting EBV-invasion of B-lymphocytes
  275. Identification and characterisation of the Plasmodium vivax rhoptry-associated protein 2
  276. High level of conservation in Plasmodium vivax merozoite surface protein 4 (PvMSP4)☆
  277. Mycobacterium tuberculosisRv2536 protein implicated in specific binding to human cell lines
  278. Gamma interferon levels and antibody production induced by two PvMSP-1 recombinant polypeptides are associated with protective immunity against P. vivax in Aotus monkeys
  279. Characterising Mycobacterium tuberculosis Rv1510c protein and determining its sequences that specifically bind to two target cell lines
  280. Identifying and characterising the Plasmodium falciparum merozoite surface protein 10 Plasmodium vivax homologue
  281. Amino terminal peptides from the Plasmodium falciparum EBA-181/JESEBL protein bind specifically to erythrocytes and inhibit in vitro merozoite invasion
  282. Cutaneous tuberculosis diagnosis in an inhospitable Amazonian region by means of telemedicine and molecular biology
  283. The T-cell receptor in primates: identifying and sequencing new owl monkey TRBV gene sub-groups
  284. Identifying Plasmodium falciparum cytoadherence-linked asexual protein 3 (CLAG 3) sequences that specifically bind to C32 cells and erythrocytes
  285. MHC class I genes in the owl monkey: mosaic organisation, convergence and loci diversity
  286. Plasmodium vivax merozoite surface protein 8 cloning, expression, and characterisation
  287. Quantifying Aotus monkey cytokines by real-time quantitative RT-PCR
  288. Liver stage antigen 3 Plasmodium falciparum peptides specifically interacting with HepG2 cells
  289. Identifying gp85-regions involved in Epstein–Barr virus binding to B-lymphocytes
  290. Plasmodium vivax Duffy binding protein: a modular evolutionary proposal
  291. Isolation and identification of mycobacteria in New World primates maintained in captivity
  292. Characterizing T-cell receptor gamma-variable gene in Aotus nancymaae owl monkey peripheral blood
  293. Splenectomised and spleen intact Aotus monkeys? immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides
  294. A highly infective Plasmodium vivax strain adapted to Aotus monkeys: Quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development
  295. alpha1 and alpha2 domains of Aotus MHC Class I and Catarrhini MHC Class Ia share similar characteristics
  296. Expression, polymorphism analysis, reticulocyte binding and serological reactivity of two Plasmodium vivax MSP-1 protein recombinant fragments
  297. Identification and polymorphism of Plasmodium vivax RBP-1 peptides which bind specifically to reticulocytes
  298. Plasmodium vivax: parasitemia determination by real-time quantitative PCR in Aotus monkeys
  299. Plasmodium vivax: functional analysis of a highly conserved PvRBP-1 protein region
  300. Plasmodium vivax: Polymorphism in the Merozoite Surface Protein 1 Gene from Wild Colombian Isolates
  301. Genetic restriction in two conserved regions of Plasmodium falciparum EBA-175t
  302. Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolates